Marc Theberge

Mr. Marc Theberge

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 January 2023 in Nature
Verified
Journal Article
Open access
PDF file
ICIain C. Clark
Iain C. Clark
PMPrakriti Mudvari
Prakriti Mudvari
STShravan Thaploo
Shravan Thaploo
SSSamuel Smith
Samuel Smith
MAMohammad Abu-Laban
Mohammad Abu-Laban
EBEli A. Boritz
Eli A. Boritz
Rare CD4 T cells that contain HIV under antiretroviral therapy represent an important barrier to HIV cure1–3, but the infeasibility of isolating and characterizing these cells in their natural state has led to uncertainty about whether they possess distinctive attributes that HIV cure-directed therapies might exploit. Here we address this challenge using a microfluidic technology that isolates the transcriptomes of HIV-infected cells based solely on the detection of HIV DNA. HIV-DNA+ memory CD4 T cells in the blood from people receiving antiretroviral therapy showed inhibition of six transcriptomic pathways, including death receptor signalling, necroptosis signalling and antiproliferative Gα12/13 signalling. Moreover, two groups of genes identified by network co-expression analysis were significantly associated with HIV-DNA+ cells. These genes (n = 145) accounted for just 0.81% of the measured transcriptome and included negative regulators of HIV transcription that were higher in HIV-DNA+ cells, positive regulators of HIV transcription that were lower in HIV-DNA+ cells, and other genes involved in RNA processing, negative regulation of mRNA translation, and regulation of cell state and fate. These findings reveal that HIV-infected memory CD4 T cells under antiretroviral therapy are a distinctive population with host gene expression patterns that favour HIV silencing, cell survival and cell proliferation, with important implications for the development of HIV cure strategies.

23 June 2021 in Viruses
Verified
Journal Article
Open access
PDF file
ADArnaud Drouin
Arnaud Drouin
MTMarc Theberge
Marc Theberge
SLSharon Y. Liu
Sharon Y. Liu
ASAllison R. Smither
Allison R. Smither
SFShelby M. Flaherty
Shelby M. Flaherty
Dahlene FuscoDahlene Fusco
Dahlene Fusco
A 59-year-old male with follicular lymphoma treated by anti-CD20-mediated B-cell depletion and ablative chemotherapy was hospitalized with a COVID-19 infection. Although the patient did not develop specific humoral immunity, he had a mild clinical course overall. The failure of all therapeutic options allowed infection to persist nearly 300 days with active accumulation of SARS-CoV-2 virus mutations. As a rescue therapy, an infusion of REGEN-COV (10933 and 10987) anti-spike monoclonal antibodies was performed 270 days from initial diagnosis. Due to partial clearance after the first dose (2.4 g), a consolidation dose (8 g) was infused six weeks later. Complete virus clearance could then be observed over the following month, after he was vaccinated with the Pfizer-BioNTech anti-COVID-19 vaccination. The successful management of this patient required prolonged enhanced quarantine, monitoring of virus mutations, pioneering clinical decisions based upon close consultation, and the coordination of multidisciplinary experts in virology, immunology, pharmacology, input from REGN, the FDA, the IRB, the health care team, the patient, and the patient’s family. Current decisions to take revolve around patient’s follicular lymphoma management, and monitoring for virus clearance persistence beyond disappearance of REGEN-COV monoclonal antibodies after anti-SARS-CoV-2 vaccination. Overall, specific guidelines for similar cases should be established.

20 March 2023 in Preprints.org
Verified
Preprint
Open access
DFDahlene Fusco
Dahlene Fusco
SLSharon Liu
Sharon Liu
MTMarc Theberge
Marc Theberge
PRPeter Reynaud
Peter Reynaud
ADArnaud Drouin
Arnaud Drouin
In New Orleans, Louisiana the population’s poor baseline health led to its establishment as an early epicenter for severe acute COVID-19. Antici-pating future outbreaks of COVID-19 and other respiratory viruses, we need to identify correlates of outcome, from real clinical experience. 89 patients were recruited into the ClinSeqSer acute COVID-19 longitudinal observational study, from the beginning of the outbreak in March to July 2020. Patients admitted for acute COVID-19 were enrolled in person. The cohort is unique as it is 68% Black, 53% female, of average age of early 60s, and prevalence of obesity and hypertension respectively of 55% and 83%. The outcomes are: 53% severe (20% fatal, 33% non-fatal) and 47% non-severe, with severe defined as death or requiring mechanical ventila-tion or high flow oxygen. Obesity and admit systolic blood pressure (SBP) >140mmHg are each associated with severe outcome and, despite respective sensitivity of 71% and 76%, specificity ~66% for both, and ac-curacy of 60% and 70% by ROC analysis, would likely provide useful predictors of outcome in critically stressed health care systems. We discuss pathophysiologic hypotheses to explain why high admit SBP is observed only in half of patients with pre-COVID hypertension and is associated with severe outcome.

28 June 2024 in medRxiv
Verified
Preprint
Open access
PDF file
Dahlene FuscoDahlene Fusco
Dahlene Fusco
SLSharon Liu
Sharon Liu
MTMarc Theberge
Marc Theberge
APAnuhya V. Pulapaka
Anuhya V. Pulapaka
YZYitian Zha
Yitian Zha
ADArnaud Drouin
Arnaud Drouin
BACKGROUND: In New Orleans, Louisiana (NOLA), the population’s very high social vulnerability led to the establishment of an early epicenter for severe acute COVID-19. Anticipating future respiratory virus outbreaks, identifying low-cost correlates of outcome relevant to special populations is crucial. METHODS: 89 patients with acute COVID-19, enrolled March to August 2020 in the ClinSeqSer longitudinal observational study. RESULTS: The cohort’s population, ∼70% Black, 53% female and 55% obese, reflects exactly that of greater urban NOLA; In contrast, pre-COVID hypertension (HTN) is 83% and 1.5 to 2-fold the state’s prevalence (43% among White, 56% among Black residents). Black patients are younger than White (∼50% vs <= 30% in 45-64 years age bracket). Outcomes were 47% severe, including 17% fatal, and 30% non-fatal (high flow or intubated), and identical by race/age. Obesity, BMI, admit systolic blood pressure (SBP), pulse BP, and CRP level, but not race, sex, age, type 2 diabetes, HTN, number or specific anti-HTN drugs, correlated with fatal and severe outcomes. Patients with admission SBP ≥140 mmHg reached severe clinical state sooner than those with lower SBP. CONCLUSIONS: The very high proportion of pre-COVID HTN in this acute COVID cohort correlates with high social vulnerability. Obesity and SBP on admission stand out as risks for fatal and severe outcomes of acute COVID. The findings support further study of acute COVID admit SBP as a potential correlate of outcome, and the potential role for interactions between a single strain of SARS CoV-2 and the renin-angiotensin-aldosterone blood pressure axis.